A Study Of PAFOLACIANINE INJECTION In Children And Adolescents

Overview

About this study

The purpose of this study is to obtain PK data on OTL38, following a single-dose injection of 0.025 mg/kg, in a pediatric population aged 2-17 years.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Be enrolled in Study 2023-6263 OR Study 2024-316849-P01
Provide written informed consent, or assent by a parent or legal guardian, for this PK study

Exclusion Criteria:

Inability to provide the required blood samples

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 12/18/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Stephanie Polites, M.D., M.P.H.	Open for enrollment	Contact information: Gina Lewis 5077386054 bmsoresearch@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Stephanie Polites, M.D., M.P.H.

Open for enrollment

Contact information:

Gina Lewis

5077386054

bmsoresearch@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials